1. André T, Shiu KK, Kim TW, et al. 2020; Pembrolizumab in microsatelliteinstability-high advanced colorectal cancer. N Engl J Med. 383:2207–2218. DOI:
10.1056/NEJMoa2017699. PMID:
33264544.
Article
4. Tougeron D, Sueur B, Zaanan A, et al. 2020; Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: an AGEO retrospective multicenter study. Int J Cancer. 147:285–296. DOI:
10.1002/ijc.32879. PMID:
31970760.
Article
5. Innocenti F, Ou FS, Qu X, et al. 2019; Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome. J Clin Oncol. 37:1217–1227. DOI:
10.1200/JCO.18.01798. PMID:
30865548. PMCID:
PMC6506418.
Article
6. Le DT, Durham JN, Smith KN, et al. 2017; Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 357:409–413. DOI:
10.1126/science.aan6733. PMID:
28596308. PMCID:
PMC5576142.
7. Le DT, Kim TW, Van Cutsem E, et al. 2020; Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 38:11–19. DOI:
10.1200/JCO.19.02107. PMID:
31725351. PMCID:
PMC7031958.
Article